Biotech shares evis­cer­at­ed in wake of Covid-19 flop

When Southamp­ton, UK-based Synair­gen last up­dat­ed its in­vestors, CEO Richard Mars­den spot­light­ed the progress it’s mak­ing on the Phase III SPRINT­ER tri­al for the lead can­di­date, SNG001, an in­haled in­ter­fer­on be­ta for­mu­la­tion, for pa­tients hos­pi­tal­ized for Covid-19. The biotech was build­ing the in­fra­struc­ture to pre­pare for an EUA in the US and sub­se­quent ap­provals around the world, and pos­i­tive da­ta from the tri­al, it added, would “rep­re­sent a ma­jor break­through in the bat­tle against Covid-19.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER